LOXO 292

Drug Profile

LOXO 292

Alternative Names: LOXO-292

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Loxo Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto oncogene protein c ret inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Sep 2017 Safety and efficacy data from a phase I trial in Solid tumour released by Loxo Oncology
  • 09 May 2017 Phase-I clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (PO) (NCT03157128)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top